Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag

Allogene Therapeutics, Inc. (ALLO) registered a loss of 38 cents per share in first-quarter 2024, in line with the Zacks Consensus Estimate. In the year-ago quarter, the company reported a loss of 69 cents.ALLO recorded revenues of $0.02 million during the quarter, missing the Zacks Consensus Estimate of $0.04 million. Revenues were down 27% year over year.Quarter in DetailResearch & development (R&D) expenses were $52.3 million, down 35% from the year-ago quarter’s level.General and administrative (G&A) ex ...